| Title | Importance of leuprolide acetate variable dosing for precocious puberty: a range of acceptable suppression. | | Author(s) | Cohen D, Janfaza M, Klein KO | | Institution | Division of Pediatric Endocrinology, Rady Children's Hospital San Diego, Department of Pediatrics, Division of Pediatric Endocrinology, University of California San Diego, San Diego, CA 92123, USA. | | Source | J Pediatr Endocrinol Metab 2009 Jul; 22(7):629-34. | | Abstract | AIM: The effect of the variation in hormonal suppression on bone maturation, growth velocity, and adult height prediction was examined during treatment with leuprolide acetate for central precocious puberty (CPP).
METHODS: Ten girls on variable doses of Lupron were studied for one year. Height, weight, body mass index, luteinizing hormone (LH), estradiol, and growth velocity were measured every 3 months. Bone age and predicted height were assessed every 6 months.
RESULTS: LH range changed from 0.5-1.4 IU/I to 0.1-2.8 IU/I. The average Lupron dose decreased from 0.33 +/- 0.11 to 0.26 +/- 0.08 mg/kg. Predicted adult height averaged 158.33 +/- 9.5cm at the start of the study and increased to 161.45 +/- 6.26 cm (p <0.01). LH and estradiol did not correlate with the rate of bone maturation, growth velocity, predicted height, or with leuprolide dose.
CONCLUSION: Variable dosing of leuprolide acetate is needed to achieve similar amounts of hormonal suppression, yet small changes in dose did not significantly change LH or estradiol levels or predicted height. | | Language | eng | | Pub Type(s) | Journal Article
Research Support, Non-U.S. Gov't
| | PubMed ID | 19774844 |
|
